On January 28 2022 Sareum Holdings plc (AIM: SAR), the specialist drug development company, reported that it has issued warrants over 29,000,000 new ordinary shares of 0.025p each in the capital of the Company to individuals who provided introductory services leading to the share subscriptions announced by the Company during 2021 (Press release, Sareum, JAN 28, 2022, View Source [SID1234607483]). The warrants have an exercise price of 5p per share, with exercise being conditional on the shares having traded at or above 7p for five consecutive days, and a subscription period that ends on 31 May 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!